The efficacy and saftey of Avastin plus S-1 compared with Docetaxel in the second line treatment of advanced lung adenocarcinoma with negtive driven gene

Trial Profile

The efficacy and saftey of Avastin plus S-1 compared with Docetaxel in the second line treatment of advanced lung adenocarcinoma with negtive driven gene

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Jan 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Docetaxel; Gimeracil/oteracil/tegafur
  • Indications Adenocarcinoma; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top